S ystematic reviews and metaanalyses are becoming more popular each year and slowly replacing the older narrative review. Systematic reviews and meta-analyses are considered some of the highest forms of evidencebased medicine. However, we need to be cautious about the application of the results of these publications. There is no standardized approach to the methodology, which means that all systematic reviews and all meta-analyses are not alike.
"Caution is the eldest child of wisdom."
-Victor Hugo
It is important that we do not immediately accept the findings of these types of evaluations without critically evaluating the methodology used by the authors. Simply reading the abstract and the conclusion could cause the reader to miss critical methodological errors caused by too narrow of a research question or literature search: excluding too much information, publication bias (failure to obtain results from unpublished studies, where the results may have been inconclusive or negative), or not looking at other sources of information (conducting the literature search using only 1 database).
A critical determinant in the development of good systematic review or meta-analyses is the methodology used to locate the clinical trials for evaluation and the method used to determine if the clinical trial will be included in the analysis. If either of these processes is flawed, then the value of the analysis is dramatically decreased or worse-it may allow an incorrect conclusion to be drawn from the combined data.
A common conclusion found at the end of many of these data analyses is that no conclusion can be found from these data. This can be a result of a poor methodology but it also can be caused by insufficient data on a given subject. For example, if you are attempting to compare various statins for a particular indication, a problem with the literature may be that clinical trials have been reported on various statins but none were conducted with the same or similar patient populations. So it is possible that there is insufficient information to reach a conclusion regarding this question, while others may attempt to combine similar but different patient populations in an attempt to formulate a conclusion-which can be dangerous.
The conclusions of the evaluation may also be short-lived. If the number of clinical trials that met the inclusion criteria for the analysis is small, then the completion of 1 large clinical trial or the results of many unpublished small clinical trials may change the conclusion of the original systematic review or meta-analyses.
When incorrect decisions are made, it may mean that practitioners may be discouraged from using effective forms of therapy or encouraged to switch therapies to a less efficacious medication; thus 'Caveat emptor' is important in our evaluation as well as the application of these results. Therefore, we all need to become better skilled at reading these types of analyses and questioning the appropriateness of their methodology before we attempt to apply conclusions derived from these analyses.
